pharmacology
Do GLP-1 drugs help as add-ons in type 1 diabetes?
Open access · cc by · source: Europe PMC
Across 11 RCTs (2,856 adults), GLP-1 RA add-on therapy modestly lowered HbA1c (−0.21%), weight (−4.04 kg), and insulin doses without more severe hypo/DKA, but GI adverse events rose (OR 2.96).
Study at a glance
- Design
- Meta-analysis / systematic review — Random-effects meta-analysis of RCTs of GLP-1 RAs as add-on to insulin in adult T1D
- N
- N=2856 · 11 trials; 2,856 participants from 1,379 screened records
- Population
- Adults with type 1 diabetes on insulin
- Outcome
- Change in HbA1c plus weight, BP, insulin doses, and selected adverse events
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
HbA1c −0.21%; weight −4.04 kg; SBP −2.57 and DBP −1.02 mmHg; prandial/basal/total insulin doses decreased. No increase in severe hypoglycemia, DKA, or severe adverse events, but gastrointestinal AEs increased (OR 2.96).
Methodology
Searched Medline/Embase/CENTRAL to May 2021 and meta-analyzed randomized trials of GLP-1 receptor agonists added to insulin in adults with type 1 diabetes (primary endpoint: HbA1c change).
Limitations
Pooled RCTs cannot settle long-term cardiorenal outcomes or individual agent ranking; GI intolerance may limit real-world uptake.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
GLP-1RAs can be studied as add-on therapy to insulin in type 1 diabetes.
A systematic/clinical synthesis evaluates glucagon-like peptide-1 receptor agonists added to insulin for type 1 diabetes—glucose and weight outcomes under insulin co-therapy.
Evidence for the claim as stated.
Different GLP-1RAs have been linked to acute pancreatitis in pharmacovigilance-style case series.
A case-series analysis associates specific GLP-1 receptor agonists with acute pancreatitis reports—useful for safety signal literacy, not incidence rates.
Scope note — efficacy add-on ≠ spontaneous pancreatitis reports
Limits the claim's scope: a different population, assay, or outcome.
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
Related papers in this topic
Same topic cluster — not a recommendation engine.